Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• TP53 gene mutations and deletions are common in Chronic Lymphocytic Leukemia (CLL), leading to p53 pathway dysfunction.
• Current targeted therapies for CLL do not directly address p53 pathway defects, contributing to treatment resistance and poor prognosis.
• The p53 pathway is considered
• Purpose_of_the_Study
• Main_Methods
• Main_Results
• Conclusions

Purpose of the Study:

• To review current therapeutic strategies targeting p53 dysfunction in Chronic Lymphocytic Leukemia (CLL).
• To highlight the challenges posed by p53 abnormalities in CLL treatment.
• To explore novel therapeutic approaches for improving outcomes in high-risk CLL patients with TP53 alterations.

Main Methods:

• Literature review of therapeutic strategies for TP53-mutated CLL.
• Analysis of emerging drug classes targeting the p53 pathway.
• Discussion of combination therapies with existing CLL treatments.

Main Results:

• Several novel therapeutic strategies are under investigation for TP53-mutated CLL.
• These include inhibitors of murine double minute 2 (MDM2), p53 reactivators, exportin 1 (XPO1) inhibitors, and ataxia-telangiectasia mutated and Rad3-related (ATR) inhibitors.
• Combinations of these agents with B-cell receptor or B-cell lymphoma-2 (BCL-2) inhibitors show promise.

Conclusions:

• Addressing p53 pathway dysfunction is critical for improving CLL treatment outcomes.
• Novel p53-targeting agents and combination therapies are expected to shape future clinical trials for high-risk CLL.
• Restoring p53 function represents a key goal in managing TP53-aberrant CLL.